Partnership expands to develop new prescription digital therapeutic for schizophrenia
Boehringer Ingelheim and Click Therapeutics have announced the launch of an expanded collaboration for development and commercialization of a second prescription digital therapeutic for those diagnosed with schizophrenia. According to a release from Boehringer, the collaboration intends to produce a novel mobile application that combines multiple clinically validated therapeutic interventions